Approximately €125 million of the vitamin-related benefits were recorded in H1 dsm-firmenich, the global innovator in nutrition, health, and beauty, has reported a strong performance for the first half of…

Approximately €125 million of the vitamin-related benefits were recorded in H1

dsm-firmenich, the global innovator in nutrition, health, and beauty, has reported a strong performance for the first half of 2025, marked by solid organic sales and earnings growth, effective execution of its strategic initiatives, and steady progress in delivering synergies following the merger.

Dimitri de Vreeze, CEO, commented, “We are pleased to report a good performance in the first six months, with good organic sales and earnings growth and the effective execution of our strategic plan. Through our combined capabilities, we continue to make good progress in delivering comprehensive cost and revenue synergies across our businesses, demonstrating the success of our merger.”

The company reported an estimated Adjusted EBITDA of €2.4 billion for the full year 2025, reflecting contributions from temporary vitamin price effects and a €200 million boost from internal cost-efficiency programs. Approximately €125 million of the vitamin-related benefits were recorded in H1.

Strategic Progress and Portfolio Realignment

dsm-firmenich continues to reshape its portfolio in line with its long-term growth strategy. As part of this, the company completed the sale of its Feed Enzymes Alliance stake to Novonesis for €1.5 billion in June 2025. The broader exit from the Animal Nutrition & Health business is also nearing completion.

This strategic divestment aims to reduce earnings volatility linked to vitamins and lower the company’s capital intensity, aligning with its focus on high-growth, high-margin consumer-focused segments.

Innovation and Growth Initiatives

Key initiatives under the 2025 Plan include:

Accelerating innovation and creation-led organic sales growth.

Delivering an additional €100 million in synergies to Adjusted EBITDA.

Completing the vitamin transformation program, expected to contribute €100 million in 2025.

Achieving a gross operating cash-to-sales ratio of over 10 per cent.

Strengthening leadership in sustainability for both people and the planet.

To date, the company has realised €165 million in synergies since the merger, including €45 million in H1 2025 alone. Additionally, the vitamin transformation program has already contributed €150 million since its launch in 2024.

Long-Term Vision

With a strong foothold in global trends such as health, nutrition, and beauty, dsm-firmenich continues to pursue its ambition of delivering science-based innovation with purpose. Its mid-term targets include:

Organic sales growth of 5–7 per cent

Adjusted EBITDA margin of 22–23 per cent

Cash-to-sales conversion exceeding 10 per cent

“With world-class talent, breakthrough science, and a unique portfolio, dsm-firmenich is well-positioned to shape emerging markets and redefine consumer experiences,” said de Vreeze. “We remain committed to delivering sustainable growth, value creation, and meaningful impact for our stakeholders.”